CD19 and lupus nephritis: The fully human autologous anti-CD19 CAR T-cell therapy, KYV-101, is currently under investigation in several multicenter clinical trials in patients with lupus nephritis, stiff person syndrome, myasthenia gravis, and multiple sclerosis to determine its therapeutic durability and safety profile.